Zhao, Mingming <br/><br/>
TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice.  [electronic resource] 

 -  Gastroenterology  06 2020 
 - 2266-2281.e27 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2020.02.033  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Bacteria--metabolism<br/>Biomarkers--blood<br/>Case-Control Studies<br/>Cross-Sectional Studies<br/>Diet, High-Fat<br/>Dysbiosis<br/>Fatty Acids, Nonesterified--metabolism<br/>Feces--microbiology<br/>Female<br/>Gastrointestinal Microbiome<br/>Humans<br/>Intestines--microbiology<br/>Lipolysis--drug effects<br/>Liver--drug effects<br/>Male<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Middle Aged<br/>Non-alcoholic Fatty Liver Disease--chemically induced<br/>Oxidation-Reduction<br/>Up-Regulation<br/>Valerates--blood<br/>Young Adult<br/>gamma-Butyrobetaine Dioxygenase--antagonists & inhibitors